A market research report issued at the beginning of the year forecast that the market for ALS drugs in several key countries would exceed $1 billion over a 10-year period.
Despite the trial not showing statistical significance on the primary or secondary efficacy endpoints, the company views the data as supportive of reldesemtiv's Phase III development
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
San Francisco-based firm, focusing on Parkinson's disease and amyotrophic lateral sclerosis, has raised $36 million to date.
2017 was a blockbuster year for drug approvals, with 46 new molecular entities and some first-of-their-kind gene therapies given the green light. But how much will the new drugs add to the medical armamentarium? And at what cost?
Late Friday, MT Pharma America broke the news that the FDA had approved its experimental amyotrophic lateral sclerosis (ALS) drug Radicava, the second-ever drug approved for ALS and the first in over 20 years.
Gaining timely results: A new ALS study bypasses many clinical trial conventions to quickly prove or disprove the efficacy of a supplement called lunasin.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In an effort to increase ALS research, Biogen is contributing $5 million - and offering to match more - to entice researchers to conduct basic science and therapeutics research in the debilitating disease.
Aquinnah's approach targets a protein called TDP-43 that has been found to accumulate in patients with neurodegenerative conditions like ALS, Alzheimer's disease and certain dementias.
Cambridge startup Amylyx just raised $1.9 million in equity and grants for its combination drug that mediates stress in mitochondria and the endoplasmic reticulum.
For the 2.5 million people who donated after participating in the Ice Bucket Challenge, how is that money being spent?
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient base – something CEO George Scangos has learned a lesson or two about by now. Two years ago, Biogen famously halted Phase 3 […]
Multiple biological pathways go awry to cause disease. Cambridge startup Catabasis is developing a platform to simultaneously modulate multiple targets in a disease pathway, with a focus on diseases like Duchenne muscular dystrophy and ALS The startup’s in the midst of a $20.4 million fundraise, according to a recent SEC filing. So far, it’s raised about […]
Researchers are now linking some ALS incidence with folks who live near large bodies of water, a new piece in Scientific American points out. It writes: About five years ago, doctors at a New Hampshire hospital noticed a pattern in their ALS patients—many of them, like Gilmore, lived near water. Since then, researchers at Dartmouth-Hitchcock Medical Center […]
A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idec’s Phase 3 trials last year: Though fast-tracked in 2009 for the indication, it failed to show any statistical efficacy in improving the symptoms or lifespan of patients with Lou […]